/Passle/596df0e43d947619ec025f26/SearchServiceImages/2022-12-19-13-42-59-346-63a06a63f636e919907aa3e4.jpg)
The FDA has denied two citizen petitions filed on behalf of the Informed Consent Action Network (ICAN) requesting the agency revoke its...
This browser is not actively supported anymore. For the best passle experience, we strongly recommend you upgrade your browser.
Add a bookmark to get started
Global Site
Back
Cortex - Life Sciences Insights
/Passle/596df0e43d947619ec025f26/MediaLibrary/Document/2022-12-08-09-42-16-699-DLAPiper-PolandLifeSciences-November2022update_thumbnail_1.png)
By
Andrzej Balicki, Ph.D.
Jolanta Dabrowicz
Przemysław Matuszewski
Urszula Grębowska
+1 more...
Show less
We first wrote about the planned amendments to the Pharmaceutical Law and certain other acts (the so-called Verticalisation Act) in...
/Passle/596df0e43d947619ec025f26/SearchServiceImages/2022-12-01-13-46-46-752-6388b046f636e913f4268c69.jpg)
The FDA recently published “Sameness Evaluations in an ANDA – Active Ingredients,” a new draft guidance detailing recommendations for...
DLA Piper is a global law firm operating through various separate and distinct legal entities. For further information about these entities and DLA Piper's structure, please refer to the Legal Notices page of this website. All rights reserved. Attorney advertising.
© 2023 DLA Piper
Email Disclaimer
Unsolicited e-mails and information sent to DLA Piper or the independent DLA Piper Relationship firms will not be considered confidential, may be disclosed to others, may not receive a response, and do not create a lawyer-client relationship with DLA Piper or any of the DLA Piper Relationship firms. Please do not include any confidential information in this message. Also, please note that our lawyers do not seek to practice law in any jurisdiction in which they are not properly permitted to do so.
